PolyNovo signs with Premier Inc

PolyNovo signs with Premier Inc

PolyNovo has signed a group purchasing agreement with Premier Inc, a major US group purchasing organisation (GPO) for the supply of NovoSorb? BTM under their Breakthrough Technology Program. That program ensures that their member hospitals have timely access to innovative products that can drive high-quality, cost-effective care. The agreement allows Premier member hospitals access to BTM at the special pricing and terms negotiated with PolyNovo.

Premier services roughly 4100 health facilities and hospital members. Of particular interest to PolyNovo are Premier’s: 

·       Over 2000 acute care hospitals including 100 designated trauma centres

·       63 Children’s hospitals including 20 designated as trauma and/or burn centres.

Effective April 1, 2021, PolyNovo will have access to Premier member hospitals and to Premier’s regional representatives, responsible for introducing new technology to members to improve utilisation and care efficiencies. PolyNovo’s marketing team and consultants will be providing the Premier team with training, materials and support to enable them to facilitate the uptake of NovoSorb BTM amongst their members. PolyNovo’s sales team can now enter hospitals that were previously restricted and will have a streamlined procurement process to facilitate faster NovoSorb? BTM adoption. 

Managing Director of PolyNovo, Paul Brennan said, “This signing with Premier, the second largest GPO in the US, is a major milestone. We have recently signed with Aptitude and First Choice. These GPO agreements put our disruptive BTM on a much larger list of hospitals than our sales team can get around in the short term. We will continue expanding our sales team into new markets to support hospitals and surgeons but now also to match the geographical footprint of the GPOs. We look forward to demonstrating improved health economic benefits for Premier hospital members and their patients.

 Senior Vice President USA, Ed Graubart said, “We estimate the top five GPOs in the US gives us access to circa 90% of the overall market. Beyond BTM the GPO relationship will also be important when we launch new products”.

Jeremy Bowden

President | Sales & Business Development Leader | Consultant

3 年

Congratulations

Anthony Kittel

CEO @ REDARC Electronics Pty Ltd | Driving Business Growth, Innovating Processes

3 年

Congratulations Paul Brennan and PolyNovo Limited team

Andrew Keenan

Retired at Enjoying Life

3 年

Outstanding work from the Polynovo Team

Fantastic achievement Paul!

要查看或添加评论,请登录

Paul Brennan的更多文章

  • Immuron strategic investment in leading gut health biotech Ateria Health

    Immuron strategic investment in leading gut health biotech Ateria Health

    Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health:…

  • Funding support US DoD ~ $4M USD

    Funding support US DoD ~ $4M USD

    Immuron (ASX:IMC) released details of their clinical trails and funding support from the US department of defence…

  • Making top 10

    Making top 10

    Humbling to be included in the list. A testament to many years of hard work with a quality team.

    23 条评论
  • PolyNovo releases Annual Report

    PolyNovo releases Annual Report

    PolyNovo has achieved many milestones throughout FY21 despite a difficult global environment with CoVid pandemic. Our…

    1 条评论
  • BTM hand surgery

    BTM hand surgery

    We use our hands for so many task often without thinking about them. Hand surgery that can deliver excellent functional…

  • New article on NovoSorb BTM

    New article on NovoSorb BTM

    There is a steady flow of new publications utilising NovoSorb BTM in complex wounds. The graphics may be confronting…

  • NovoSorb BTM in Complex Wounds- New

    NovoSorb BTM in Complex Wounds- New

    https://onlinelibrary.wiley.

  • Interview on Australia's Patent Box

    Interview on Australia's Patent Box

    https://iview.abc.

    1 条评论
  • PolyNovo SynPath first patient in chronic wound reimbursement trial

    PolyNovo SynPath first patient in chronic wound reimbursement trial

    PolyNovo is pleased to announce it has received final Independent Review Board (IRB) ethics approval for the first…

    3 条评论
  • PolyNovo enters Denmark, Norway and Iceland

    PolyNovo enters Denmark, Norway and Iceland

    PolyNovo (PNV) has expanded into the Danish, Norwegian and Icelandic medical device markets with the appointment of…

    4 条评论

社区洞察

其他会员也浏览了